{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:07:41Z","timestamp":1795136861703,"version":"4.10.3"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate-specific membrane antigen (PSMA), also known as GCPII, has emerged as a significant target in the diagnosis and treatment of prostate cancer. This perspective highlights the journey that led to the development of PSMA-targeted urea-based ligands, culminating in the clinical success of radiopharmaceuticals such as Pylarify and Pluvicto. Originating from research at Georgetown University, early PSMA inhibitors evolved through rational drug design starting from the neurotransmitter NAAG and a phosphonic acid derivative to simplified Glu-urea scaffolds with exceptional inhibitory activity. These ligands enabled the creation of both diagnostic and therapeutic radioligands, as well as emerging small molecule drug conjugates (SMDCs). Ongoing innovation includes bifunctional antigen targeting, alternative PSMA-binding motifs, and efforts to develop brain-penetrant GCPII inhibitors. This mini-perspective reveals how a collaborative chemistry\/biology project not only redefined prostate cancer imaging and therapy but also opened new avenues for targeted cancer theranostics.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01593","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:01:16Z","timestamp":1759759276000},"page":"20972-20978","source":"Crossref","is-referenced-by-count":5,"title":["How a Medicinal\nChemistry Project Changed the Way Prostate Cancer is Diagnosed and\nTreated"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2541-2826","authenticated-orcid":true,"given":"Alan P.","family":"Kozikowski","sequence":"first","affiliation":[{"name":"Prostate Theranostics Inc. , 1 Research Court, Suite 450 , , ,","place":["Rockville, Maryland, United States, 20850"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Neale","sequence":"additional","affiliation":[{"name":"Georgetown University , , , ,","place":["Washington, District of Columbia, United States, 20057"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026072715532368800_cit1","volume-title":"Cancer Facts & Figures","author":"American Cancer Society.","year":"2024"},{"issue":"16","key":"2026072715532368800_cit2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate\nCancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"2026072715532368800_cit3","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T)\nin prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026072715532368800_cit4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ctrv.2009.06.001","article-title":"Targeted therapeutic approaches for hormone-refractory\nprostate cancer","volume":"36","author":"Stavridi","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"5B","key":"2026072715532368800_cit5","first-page":"927","article-title":"Monoclonal\nantibodies to a new antigenic marker in epithelial prostatic cells\nand serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer\nRes."},{"issue":"3A Suppl","key":"2026072715532368800_cit6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0090-4295(97)00177-5","article-title":"Characterization\nand glutamyl preferring carboxypeptidase function of prostate specific\nmembrane antigen: a novel folate hydrolase","volume":"49","author":"Heston","year":"1997","journal-title":"Urology"},{"issue":"1\u20132","key":"2026072715532368800_cit7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-4781(98)00200-0","article-title":"Mapping,\ngenomic organization and promoter analysis of the human prostate-specific\nmembrane antigen gene","volume":"1443","author":"O\u2019Keefe","year":"1998","journal-title":"Biochim. Biophys. Acta,\nGene Struct. Expression"},{"issue":"2","key":"2026072715532368800_cit8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1073\/pnas.93.2.749","article-title":"Prostate-specific\nmembrane antigen is a hydrolase with substrate and pharmacologic characteristics\nof a neuropeptidase","volume":"93","author":"Carter","year":"1996","journal-title":"Proc. Natl. Acad. Sci.\nU.S.A."},{"issue":"6","key":"2026072715532368800_cit9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1110\/ps.04622104","article-title":"Identification of the N-glycosylation\nsites on glutamate carboxypeptidase II necessary for proteolytic activity","volume":"13","author":"Barinka","year":"2004","journal-title":"Protein Sci."},{"issue":"21","key":"2026072715532368800_cit10","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1111\/bph.13576","article-title":"The therapeutic and diagnostic potential of the prostate\nspecific membrane antigen\/glutamate carboxypeptidase II (PSMA\/GCPII)\nin cancer and neurological disease","volume":"173","author":"Evans","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"2026072715532368800_cit11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific\nmembrane antigen cleavage of vitamin B9 stimulates oncogenic signaling\nthrough metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J.\nExp. Med."},{"issue":"21","key":"2026072715532368800_cit12","doi-asserted-by":"publisher","first-page":"9070","DOI":"10.1158\/0008-5472.CAN-08-2328","article-title":"Moderate\nexpression of prostate-specific membrane antigen, a tissue differentiation\nantigen and folate hydrolase, facilitates prostate carcinogenesis","volume":"68","author":"Yao","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"2026072715532368800_cit13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1046\/j.1471-4159.2000.0750443.x","article-title":"N-Acetylaspartylglutamate:\nthe most abundant peptide neurotransmitter in the mammalian central\nnervous system","volume":"75","author":"Neale","year":"2000","journal-title":"J. Neurochem."},{"key":"2026072715532368800_cit14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.nlm.2019.01.006","article-title":"A role for\nN-acetylaspartylglutamate (NAAG) and mGluR3 in cognition","volume":"158","author":"Neale","year":"2019","journal-title":"Neurobiol. Learn. Mem."},{"key":"2026072715532368800_cit15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101722","article-title":"N-acetylaspartylglutamate (NAAG)\nand glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme\nsystem with multiple clinical applications","volume":"184","author":"Neale","year":"2020","journal-title":"Prog. Neurobiol."},{"issue":"23","key":"2026072715532368800_cit16","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-15-0552","article-title":"A Phase I\/II Study\nfor Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging\nAgent for Metastatic Prostate Cancer","volume":"21","author":"Pandit-Taskar","year":"2015","journal-title":"Clin.\nCancer Res."},{"issue":"1","key":"2026072715532368800_cit17","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal\nand malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"17\u201318","key":"2026072715532368800_cit18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.drudis.2007.07.010","article-title":"Progress in the discovery and development of glutamate\ncarboxypeptidase II inhibitors","volume":"12","author":"Tsukamoto","year":"2007","journal-title":"Drug Discovery\nToday"},{"issue":"5","key":"2026072715532368800_cit19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1021\/jm9905559","article-title":"Dual function\nglutamate-related ligands: discovery of a novel, potent inhibitor\nof glutamate carboxypeptidase II possessing mGluR3 agonist activity","volume":"43","author":"Nan","year":"2000","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026072715532368800_cit20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design\nof remarkably simple, yet potent urea-based inhibitors of glutamate\ncarboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026072715532368800_cit21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes\nof glutamate carboxypeptidase II: efficacy as analgesic agents","volume":"47","author":"Kozikowski","year":"2004","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026072715532368800_cit22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nrd1903","article-title":"NAAG peptidase inhibitors and their potential for diagnosis\nand therapy","volume":"4","author":"Zhou","year":"2005","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"10","key":"2026072715532368800_cit23","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","article-title":"N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine,\n[18F]DCFBC: a new imaging probe for prostate cancer","volume":"14","author":"Mease","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"2026072715532368800_cit24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","article-title":"Biodistribution,\ntumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight\ninhibitor of prostate-specific membrane antigen, in patients with\nmetastatic prostate cancer","volume":"53","author":"Cho","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"24","key":"2026072715532368800_cit25","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase\nII and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J. Med. Chem."},{"issue":"15","key":"2026072715532368800_cit26","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1021\/jm800111u","article-title":"Synthesis and evaluation\nof technetium-99m- and rhenium-labeled inhibitors of the prostate-specific\nmembrane antigen (PSMA)","volume":"51","author":"Banerjee","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"2026072715532368800_cit27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.schres.2007.11.013","article-title":"Dysregulation of glutamate carboxypeptidase II in psychiatric\ndisease","volume":"99","author":"Guilarte","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"2026072715532368800_cit28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1162\/153535002320162750","article-title":"11C-MCG:\nsynthesis, uptake selectivity, and primate PET of a probe for glutamate\ncarboxypeptidase II (NAALADase)","volume":"1","author":"Pomper","year":"2002","journal-title":"Mol. Imaging"},{"issue":"11","key":"2026072715532368800_cit29","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small-molecule ligands for prostate-specific\nmembrane antigen: in vivo imaging in experimental models of prostate\ncancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026072715532368800_cit30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm800994j","article-title":"A series\nof halogenated heterodimeric inhibitors of prostate specific membrane\nantigen (PSMA) as radiolabeled probes for targeting prostate cancer","volume":"52","author":"Maresca","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026072715532368800_cit31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1659-0010","article-title":"[18F]DCFPyL PET\/CT\nfor Imaging of Prostate Cancer","volume":"61","author":"Rowe","year":"2022","journal-title":"Nuklearmedizin"},{"issue":"8","key":"2026072715532368800_cit32","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-targeted radiotheranostics in modern nuclear medicine:\nthen, now, and what of the future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"key":"2026072715532368800_cit33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nucmedbio.2021.12.005","article-title":"Recent advancements in (18)F-labeled\nPSMA targeting PET radiopharmaceuticals","volume":"106\u2013107","author":"Piron","year":"2022","journal-title":"Nucl.\nMed. Biol."},{"issue":"22","key":"2026072715532368800_cit34","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.1021\/acs.jmedchem.2c01423","article-title":"Enhancing\nthe Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates\nby Linker Stabilization and Conjugation to Transthyretin Binding Ligand","volume":"65","author":"Amin","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026072715532368800_cit35","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112065","article-title":"Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast\nCancer","volume":"13","author":"Najjar","year":"2022","journal-title":"Genes"},{"issue":"10","key":"2026072715532368800_cit36","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2967\/jnumed.119.226449","article-title":"Effect of External Cooling on (177)Lu-PSMA Uptake by\nthe Parotid Glands","volume":"60","author":"Yilmaz","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026072715532368800_cit37","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00259-024-07044-7","article-title":"JHU-2545 preferentially\nshields salivary glands and kidneys during PSMA-targeted imaging","volume":"52","author":"Nedelcovych","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026072715532368800_cit38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/pros.23136","article-title":"The STEAP1(262\u2013270) peptide\nencapsulated into PLGA microspheres elicits strong cytotoxic T cell\nimmunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy\nagainst prostate carcinoma","volume":"76","author":"Herrmann","year":"2016","journal-title":"Prostate"},{"issue":"11","key":"2026072715532368800_cit39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/acsmedchemlett.8b00318","article-title":"2-Aminoadipic\nAcid-C(O)-Glutamate Based Prostate-Specific Membrane Antigen Ligands\nfor Potential Use as Theranostics","volume":"9","author":"Nakajima","year":"2018","journal-title":"ACS Med.\nChem. Lett."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01593","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/20\/20972\/66291711\/acs.jmedchem.5c01593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/20\/20972\/66291711\/acs.jmedchem.5c01593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:53:27Z","timestamp":1785182007000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/20\/20972\/5234630\/How-a-Medicinal-Chemistry-Project-Changed-the-Way"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":39,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,10,23]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01593","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}